Adebrelimab plus chemo-radiation for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation for people with limited-stage small cell lung cancer. After the initial treatment, adebrelimab is continued alone to help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with limited-stage small cell lung cancer (cancer that has not spread beyond one side of the chest).
- You have not had more than 2 rounds of chemotherapy, or you have not had any chemotherapy yet.
- You are in generally good health (able to do daily activities without help) and have adequate lung and organ function.
- You agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether adding a drug called adebrelimab (SHR-1316) to standard chemotherapy before treatment leads to more successful surgery and/or radiation for limited-stage small cell lung cancer. It’s for people who have not had any prior cancer treatment and can undergo planned “curative” treatment after 4 cycles.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation treatment for patients with advanced non-small cell lung cancer that cannot be surgically removed. The goal is to improve how well treatment works and help patients live longer.
This trial tests a drug called Adebrelimab as a maintenance therapy after you finish chemotherapy and radiation (given in smaller, more frequent doses) for limited-stage small cell lung cancer. The goal is to see if it helps keep the cancer from coming back.
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
This trial tests a maintenance drug called Adebrelimab after initial chemo with or without radiation for limited-stage small cell lung cancer. It aims to see if continuing the drug helps keep the cancer from coming back.
This trial tests a treatment plan that combines a short course of radiation with chemotherapy and an immunotherapy drug (adebrelimab). It is for people with limited-stage small cell lung cancer who haven't had treatment yet.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.